Human Chorionic Gonadotropin (HCG) Market Size & Share, by Technology (Natural Source Extraction and Recombinant Technology); Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment); End-User (Fertility Clinics, Research Institutes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3160
  • Published Date: Sep 23, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Human Chorionic Gonadotropin (HCG) Market size was valued at USD 741.27 million in 2023 and is anticipated to cross USD 1.70 billion by the end of 2036, registering more than 6.6% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of human chorionic gonadotropin is estimated at USD 780.41 million.

The increasing infertility rate globally, along with the growing investment in the innovation of technologically improved products are expected to fuel the development of this market. The growth of the market can also be attributed to factors such as the increasing awareness among the population towards gynaecological problems and the rising middle-class population in the emerging economies on a global level. According to the data collected from the World Health Organization (WHO), in September 2020, approximately 48 million couples and 186 million individuals across the globe lives with infertility. Such increasing number of infertility rate has rapidly increased the requirement for human chorionic gonadotropin (HCG) in the market. The rising shift of traditional lifestyles to western lifestyle adoption along with poor dietary habits among individuals are expected to make a significant contribution to the soaring revenue of the human chorionic gonadotropin (HCG) market. Gynaecology is one of the important branch of medicine concerned with medical issues among women. As a result, it includes conditions associated to wellbeing of women and their testing and screening methodology. Women’s body is predominantly prone to various types of cancer, including, breast cancer, cervical cancer, and ovarian cancer. Other rising medical conditions such as polycystic ovarian disorder, infertility, menopause, depression, osteoporosis, and obesity. Human chorionic gonadotropin (hGC) is a hormone produced by placenta in a pregnant women and is a type of gonadotropin hormone.


Global-Human-Chorionic-Gonadotropin-Test-Market-Overview
Get more information on this report: Request Free Sample PDF

Human Chorionic Gonadotropin (HCG) Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Cases of Infertility
  • Increasing in the Incidence of Male Hypogonadism

Challenges

  • Regulations & Warnings Issued by FDA
  • Lack of Accuracy & Specificity

Human Chorionic Gonadotropin (HCG) Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

6.6%

Base Year Market Size (2023)

USD 741.27 million

Forecast Year Market Size (2036)

USD 1.70 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, South Korea, Malaysia, Australia, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Human Chorionic Gonadotropin (HCG) Segmentation

The human chorionic gonadotropin (HCG) market is segmented based on technology into natural source extraction, and recombinant technology, out of which, natural source extraction segment is anticipated to grab the largest share by the end of 2021 on account of increased number investments by the major players to extract gonadotropins from natural source. However, increasing government approval of digital devices globally is also projected to contribute to the growth of the recombinant technology segment is expected to increase with a rapid growth rate on the back of increasing availability of recombinant hCGs during the forecast period.

Based on therapeutic area, the female infertility segment held the largest share in the global Human chorionic gonadotropin (HCG) market on the back of growing concern and awareness for infertility among the couples and individuals across the developing and under-developed countries.

Our in-depth analysis of the global market includes the following segments

By Technology

  • Natural Source Extraction
  • Recombinant Technology

By Therapeutic Area

  • Female Infertility Treatment
  • Male Hypogonadism
  • Oligospermic Treatment
  • Others

By End-User

 

  • Fertility Clinics
  • Research Institutes
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Human Chorionic Gonadotropin (HCG) Industry - Regional Synopsis

APAC Market Statistics

Geographically, the human chorionic gonadotropin (HCG) market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. Asia Pacific industry is poised to dominate majority revenue share by 2036, owing to growing population, increasing concern and awareness among the individuals in the region.

North America Market Analysis

Furthermore, in 2021, the human chorionic gonadotropin (HCG) market in North America is evaluated to occupy the largest share in terms of revenue, owing to the increasing incidence of infertility among the women aged between 15-44 years in the region. According to the report published by the Centers for Disease Control and Prevention (CDC), annually approximately 10% of the women which accounts for 6.1 million in the United States face difficulty to conceive or staying pregnant. Such increasing issues during the reproductive age among the individuals and couples is further expected to drive the demand for Human chorionic gonadotropin (HCG) in the North American countries. Alternatively, the market in Europe is also anticipated to occupy a significant share in the global Human chorionic gonadotropin (HCG) market on account of its proven success in terms of technology development in the region.

Research Nester
Human-Chorionic-Gonadotropin-Test-Market-Share
Get more information on this report: Request Free Sample PDF

Companies Dominating the Human Chorionic Gonadotropin (HCG) Landscape

    • Merck & Co.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Cigna
    • Lee BioSolutions
    • Swiss Precision Diagnostics GmbH
    • Abbott Laboratories
    • Quidel Corporation
    • Geratherm Medical AG
    • bioMérieux SA
    • CIGA Healthcare Ltd

In the News

  • May 2020: Tolmar Inc., one of the leading pharmaceutical company in the U.S., announced that the U.S. Food and Drug Administration (FDA) has approved their drug application for FENSOLVI, which is a leuprolide acetate for injectable suspension to treat pediatric patients with two years of age and older with central gonadotropin-dependent precocious puberty (CPP).
  • January 2019: Ferring Pharmaceuticals based in Switzerland, announced that they have strategically acquired the United States commercialization rights for generic Ganirelix Acetate Injection to prevent premature ovulation in women undergoing fertility treatment.

Author Credits:  Radhika Pawar


  • Report ID: 3160
  • Published Date: Sep 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising cases of infertility and increasing in the incidence of male hypogonadism are the key factors driving market growth.

The market is anticipated to attain a high CAGR over the forecast period, i.e., 2021-2029.

With respect to therapeutic area, the female infertility segment is anticipated to hold the largest market share owing to the growing number of infertility cases among the young women.

The market in Asia Pacific region will provide ample growth opportunities owing to the increasing population and infertility among individuals.

The major players dominating the Human Chorionic Gonadotropin (hCG) Test market are Merck & Co., Cigna, Lee BioSolutions, Swiss Precision Diagnostics GmbH, Abbott Laboratories, Quidel Corporation, Geratherm Medical AG, bioMérieux SA, CIGA Healthcare Ltd, and Others.
Human Chorionic Gonadotropin Test Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample